Incyte Adds PD-1 Inhibitor To Its Promising IDO With MacroGenics Deal

Incyte's potential $900m licensing agreement with MacroGenics for its clinical-stage checkpoint inhibitor is considered a strong strategic move for Incyte, with the PD-1 inhibitor, MGA012, likely to become a cornerstone of its immune-oncology combination cancer therapies.

Hand Shake
A significant agreement for both companies. • Source: Shutterstock

Incyte Corp. signaled its intention to boost its immuno-oncology activities on Oct. 25 with the announcement that it was licensing MacroGenics Inc.'s early clinical-stage PD-1 inhibitor, MGA012, for worldwide development and commercialization in all indications, although MacroGenics will retain the right to develop its pipeline assets in combination with MGA012.

Having a PD-1 inhibitor of your own to combine with your other in-house anticancer compounds aids smaller companies avoid losing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer